New classes of glaucoma medical treatment
10.5124/jkma.2019.62.9.497
- Author:
Jin A CHOI
1
Author Information
1. Department of Ophthalmology and Visual Science, St. Vincent's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea. jinah616@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Glaucoma;
Ocular hypertension;
Intraocular pressure;
Drug development
- MeSH:
Adenosine;
Aqueous Humor;
Axons;
Carbonic Anhydrase Inhibitors;
Glaucoma;
Humans;
Intraocular Pressure;
Nitric Oxide Donors;
Ocular Hypertension;
Optic Disk;
Parasympathomimetics;
Prostaglandins, Synthetic;
rho-Associated Kinases;
Trabecular Meshwork;
Visual Fields
- From:Journal of the Korean Medical Association
2019;62(9):497-504
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Glaucoma is a progressive degenerative disease of the optic nerve head, characterized by a specific pattern of axonal loss and visual field deterioration. This review aims at introducing the different novel pharmacologic agents for its treatment, as well as their mechanisms. Most glaucoma patients require lifelong care and individualized treatment. Intraocular pressure (IOP), which is regulated by aqueous humor production, outflow via the trabecular meshwork (parasympathomimetics only) and uveoscleral outflow pathways, is currently the only treatable target for glaucoma treatment. Conventional glaucoma medications are categorized as β blockers, α agonists, carbonic anhydrase inhibitors, parasympathomimetics, and prostaglandin analogues. The development of basic research-derived novel classes of pharmacologic agents features novel action mechanisms, which are different from those of conventional medications. New classes of recently approved or clinical trial-tested medications include Rho-kinase inhibitors, nitric oxide donors, adenosine agonists, and prostaglandin analogs targeting E-type prostanoid receptors, etc. Their integration and future development will facilitate the expansion and customization of therapeutic options.
